# US 10,500,248 B2 · Method for treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,500,248 B2
- Document ID: US10500248B2
- Status: Granted
- Kind: B2
- Application number: 15/552,350
- Filed: 2016-03-29
- Published: 2018-02-15
- Granted: 2019-12-10
- Earliest claimed: 2015-03-30
- Assignees: Sunnybrook Research Institute
- Applicants: Sunnybrook Research Institute
- Inventors: Laurence H. Klotz; Vasundara Venkateswaran
- Web page: https://patentgrep.com/patent/US10500248B2

## CPC

- A61K 38/095: Oxytocins; Vasopressins; Related peptides
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to a method of treating prostate cancer comprising administering to a subject in need thereof a therapeutically effective amount of a vasopressin analogue.

## Claims

### Claim 1

A method for the treatment of prostate cancer comprising administering to a subject in need thereof, a therapeutically effective amount of desmopressin and a therapeutically effective amount of docetaxel, wherein the prostate cancer is metastatic castrate-resistant prostate cancer.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said desmopressin reduces uPA protein expression.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said desmopressin reduces tumour volume.

### Claim 4 (depends on 1)

The method according to claim 1, wherein said desmopressin inhibits cell proliferation.

### Claim 5 (depends on 1)

The method according to claim 1, wherein said desmopressin reduces cell invasion and/or migration.